Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 13601 - 13625 of 15151 in total
BHT-3034 is a DNA plasmid vaccine immunotherapy under investigation for the treatment of myasthenia gravis.
Investigational
SIS-101-ADO is a siRNA therapeutic under investigation for the treatment of Autosomal Dominant Osteopetrosis Type 2 (ADO2).
Investigational
PBKR03 is a non-replicating recombinant adeno-associated virus serotype hu68 vector, containing a transgene encoding the human galactosylceramidase (GALC) enzyme.
Investigational
ATX-01 is an antimiR, a chemically modified antisense oligonucleotide, designed to target microRNA 23b (miR-23b).
Investigational
Investigational
Investigational
Investigational
Investigational
LYT-200 is a fully human IgG4 monoclonal antibody directed against galectin-9.
Investigational
Investigational
Investigational
Investigational
Investigational
FCX-013 consists of human dermal fibroblasts genetically modified with a lentiviral vector expressing metalloproteinase-1 (MMP-1).
Investigational
Investigational
Investigational
Investigational
AMP-101 is a gene therapy comprising an adeno-associated virus type 9 (AAV9) vector encoding the human Dok-7 protein. It is under investigation for the treatment of Dok-7-associated myasthenia.
Investigational
Investigational
EXOB-001 consists of extracellular vesicles derived from cultured human umbilical cord mesenchymal stromal cells.
Investigational
DCN-tCRK is a recombinant, multi-functional fusion protein consisting of human decorin fused to the C-terminal vascular homing peptide tCRK.
Investigational
BREN-02 is a recombinant human homeoprotein Engrailed 1 (rhEN1).
Investigational
Investigational
Investigational
Displaying drugs 13601 - 13625 of 15151 in total